Sanyal 2024 — Survodutide in MASH and Fibrosis

New England Journal of Medicine·July 25, 2024

Arun J. Sanyal, et al.

Summary

Survodutide produced significant dose-dependent improvement in MASH resolution without worsening fibrosis in a phase 2 trial.

Study Details

Study Design

Phase 2 randomized placebo-controlled trial

Indication

Metabolic dysfunction-associated steatohepatitis with fibrosis

Intervention

Survodutide vs placebo for 48 weeks

Species

Human

Sample Size

293 subjects

Risk of Bias Assessment

Sponsor-funded phase 2